Neal Walker

Neal Walker, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Aclaris Therapeutics, Inc. and Aldeyra Therapeutics, Inc. Between 1 June 2021 and 3 February 2026, the trades on record add up to 33 filings.

Sales make up the whole of the open-market record (5 sales, €1.9M). Other entries cover 4 share grants and 24 option exercises.

Most recently, on 5 February 2026, the filings show an option exercise in Aclaris Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.